Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-907351 (XL184)
BMS-907351 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-907351 (XL184) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-907351 (XL184) | DRUG | Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent |
Inclusion Criteria: * Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate * Life expectancy of at least 3 months * Eastern Cooperative Oncology Group performance 0-2 Exclusion Criteria: * Subject has uncontrolled intercurrent illness
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
BMS-907351 is an investigational small molecule being studied for the treatment of neoplasms, specifically solid tumors. It is in Phase 1 clinical development in Japan, where it was evaluated in a multiple ascending dose study in patients with solid tumors. It is not approved for any indication.
BMS-907351 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company sponsored the Phase 1 trial of the drug in Japan.
BMS-907351 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug remains investigational and has not been approved by the FDA or any other regulatory agency for any indication.
BMS-907351 has been studied in one completed Phase 1 trial, NCT01018745, titled Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan. The trial enrolled 3 patients with neoplasms in Japan and was uncontrolled, non-randomized, and not double-blind.
Yes, BMS-907351 is also known as XL184. The two names refer to the same investigational small molecule. The Phase 1 trial NCT01018745 lists the drug as BMS-907351 (XL184).